Core Insights - The independent study published in the journal Cancers demonstrates that IceCure Medical's ProSense® cryoablation system is a safe and effective local treatment for breast cancer, particularly in a higher-risk patient population with metastatic disease and larger tumors [4][11][14] - The study reported an 8.9% recurrence rate among 45 patients, all of whom had previously undergone various therapies, indicating the efficacy of ProSense® in managing more complex cases of breast cancer [4][11] - The results support the broader application of ProSense® across different stages of breast cancer, from early-stage to metastatic and recurrent disease, enhancing its value proposition in the market [8][11] Company Overview - IceCure Medical (Nasdaq: ICCM) specializes in developing and marketing advanced liquid-nitrogen-based cryoablation therapy, providing a minimally invasive alternative to surgical tumor removal [2][12] - The ProSense® system is designed to create large lethal zones for effective tumor destruction, applicable to various cancers including breast, kidney, lung, and liver [9][12] - The company emphasizes the advantages of its technology, including reduced recovery time, lower pain levels, and minimized surgical risks, making it suitable for outpatient procedures [15]

"This latest FDA regulatory clearance further validates the safety and efficacy of our platform cryoablation technology," commented Eyal Shamir, IceCure's Chief Executive Officer. "The next-generation XSense™ system is cleared for the same indications as our flagship ProSense® system and we believe it has future potential to address other indications in the U.S. for significant indications with unmet needs. Through our innovation, IceCure is a global leader in liquid nitrogen-based cryoablation systems that ...

Recent insider open-market stock purchases demonstrate continued confidence in the Company CAESAREA, Israel, June 18, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the Company's management, will participate in the Northland Capital Markets Virtual Growth Conference on Tuesday, ...

IceCure Medical Ltd. (ICCM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Since a chan ...

Demonstrates public health importance of assessing ProSense®'s potential to offer optimal treatment that benefits women with early-stage breast cancer Patients, patient advocacy groups, doctors, and the general public will be welcome to participate and comment in the open public hearing IceCure welcomes a transparent public forum to share ICE3 study results and show how ProSense® cryoablation could potentially offer a minimally invasive alternative treatment to women diagnosed with early-stage breast cancer ...

IceCure Medical Ltd (NASDAQ:ICCM) Q1 2024 Earnings Conference Call May 28, 2024 11:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer Tlalit Bussi Tel-Tzure - VP, Business Development & Global Marketing Ronen Tsimerman - Chief Financial Officer & Chief Operating Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Anthony Vendetti - Maxim Group Ben Haynor - Lake Street Capital Markets Yi Chen - H.C. Wainwright Operator Good mor ...

Exhibit 99.1 IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024 CAESAREA, Israel, May 28, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2024. During the quarter, ...

30% sales growth reflects continued adoption of ProSense® in the U.S. and other global markets Major milestones achieved: - Completion of landmark ICE3 trial for breast cancer - Positive final ICE3 trial data Awaiting FDA Decision Independent studies performed globally continue to demonstrate ProSense®'s efficacy and safety across numerous indications Conference call to be held today at 11:00 am Eastern Time CAESAREA, Israel, May 28, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceC ...

About IceCure Medical CAESAREA, Israel, May 21, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release containing its financial and operational results as of and for the three months ended March 31, 2024 before the Nasdaq Stock Market opens on Tuesday, May 28, 2024. The ...

IceCure Medical (ICCM) recently announced that the company had submitted final data to the FDA requesting market authorization for its ProSense System.ProSense is designed to provide cryoablation, an outpatient technique that treats breast cancer in 20–40 minutes. It requests FDA approval to use cryoablation and adjuvant hormone therapy in the treatment of individuals with early-stage T1 invasive breast cancer.Price PerformanceIn the past six months, ICCM shares have gained 41.8% compared with the industry’ ...